COMPARATIVE EFFECTIVENESS OF GEFITINIB, ERLOTINIB, AFATINIB AND CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS

被引：0
|
作者：
Lopes, Gilberto [1 ]
Haaland, Benjamin [2 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD 21218 USA
[2] Duke Nus Grad Med Sch, Off Clin Sci, Ctr Quantitat Med, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Epidermal growth factor receptor; comparative effectiveness; tyrosine kinase inhibitor; indirect comparison;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.11-015
引用
收藏
页码：S895 / S896
页数：2
相关论文
共 50 条
  • [21] Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib
    Heigener, David F.
    Reck, Martin
    [J]. ADVANCES IN THERAPY, 2011, 28 (02) : 126 - 133
  • [22] COST-UTILITY ANALYSIS OF FIRST-LINE GEFITINIB, ERLOTINIB AND AFATINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS
    Holleman, M. S.
    Zaim, R.
    Uyl-De Groot, C. A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A740 - A741
  • [23] Mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC).
    Sonobe, M
    Katakura, H
    Adachi, T
    Wada, H
    Tanaka, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 637S - 637S
  • [24] Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
    Lin, Yen-Ting
    Chen, Jin-Shing
    Liao, Wei-Yu
    Ho, Chao-Chi
    Hsu, Chia-Lin
    Yang, Ching-Yao
    Chen, Kuan-Yu
    Lee, Jih-Hsiang
    Lin, Zhong-Zhe
    Shih, Jin-Yuan
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (11) : 2887 - 2896
  • [25] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS (TKIS) ERLOTINIB AND GEFITINIB IN THE TREATMENT OF PATIENTS WITH BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC)
    Naskhletashvili, D. R.
    Gorbounova, V.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 435 - 435
  • [26] Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)
    Porta, R.
    Queralt, C.
    Cardenal, F.
    Mayo, C.
    Provencio, M.
    Camps, C.
    Isla, D.
    Gonzalez-Larriba, J.
    Taron, M.
    Rosell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] COST-EFFECTIVENESS OF FIRST LINE TYROSINE KINASE INHIBITOR TREATMENT IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATED ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS: A MARKOV MODEL
    Borget, Isabelle
    Vergnenegre, Alain
    Chouaid, Christos
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1269 - S1269
  • [28] COST EFFECTIVENESS OF FIRST LINE TYROSINE KINASE INHIBITOR TREATMENT IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS: A MARKOV MODEL
    Borget, I
    Vergnenegre, A.
    Chouaid, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A454 - A454
  • [29] First-line erlotinib in stage IV non-small-cell lung cancer (NSCLC) patients (P) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Massuti, Bartomeu
    Reguart, Noemi
    Vivanco, Guillermo Lopez
    Provencio, Mariano
    Isla, Dolores
    Camps, Carlos
    Ares, Luis Paz
    Pradas, Anna
    Taron, Miquel
    Rosell, Rafael
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 216 - 216
  • [30] First-line erlotinib in stage IV non-small cell lung cancer (NSCLC) patients (pts) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Massuti, B.
    Porta, R.
    Paz-Ares, L.
    Cardenal, F.
    Lopez-Vivanco, G.
    Provencio, M.
    Isla, D.
    Pradas, A.
    Taron, M.
    Rosell, R.
    [J]. LUNG CANCER, 2006, 52 : S25 - S26
12345